Cyto-Facto
GMP-compliant manufacturing services for gene and cell therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
* | JPY1.2b | Series B | |
| Total Funding | 000k | ||
Related Content
Cyto-Facto Inc., founded in October 2022 by Shin Kawamata, is a contract development and manufacturing organization (CDMO) specializing in gene and cell therapy products. The company spun out of the Foundation for Biomedical Research and Innovation at Kobe (FBRI) in April 2023, taking over the operations of the Cell Therapy Development Center (RDC). The RDC was notably the first site in Asia to commercially produce the CAR-T cell therapy product, Kymriah, for Novartis.
The company provides a range of services including GMP-compliant manufacturing, quality control testing, process development, and consulting for cell and gene preparations. It serves biotechnology and pharmaceutical companies by manufacturing investigational products for clinical trials and commercial-scale products. Cyto-Facto handles therapies using products like CAR-T cells and mesenchymal stem cells (MSC). Its business model is based on offering contract manufacturing (CMO) and contract development and manufacturing (CDMO) services.
A key product developed by the company is CytoFactory 4.0™, a cloud-based, GxP-compliant manufacturing management system designed to digitize and optimize the entire cell manufacturing process. This platform handles everything from raw material intake and inventory control to cell processing, quality testing, and shipment, aiming to reduce costs and improve efficiency. By making manufacturing records fully digital, it also supports regulatory compliance and process improvement.
The founder and CEO, Shin Kawamata, MD, PhD, has an extensive background in pathology, hematology, and stem cell biology, with experience at Novartis Research Institute and Stanford University. He served as the director of the RDC at FBRI before establishing Cyto-Facto. The company has secured Series A and B funding from investors including MPower Partners, D3, Asahi Kasei, Mitsubishi Corporation, and Kobe University Capital.
Keywords: cell therapy, gene therapy, CDMO, CMO, GMP manufacturing, CAR-T, regenerative medicine, mesenchymal stem cells, contract manufacturing, quality control, process development, CytoFactory 4.0, cell processing, biopharmaceutical services, investigational new drugs, biologics manufacturing, clinical trials support, pharmaceutical manufacturing, advanced therapies, biotechnology